Joël Mercier, Massimo Bani, Anny-Odile Colson, Massimiliano Germani, Marianna Lalla, Christophe Plisson, Mickael Huiban, Graham Searle, François-Xavier Mathy, Richard Nicholl, Christian Otoul, Johan Willem Smit, Vanja van Asch, Michel Wagneur, Ralph Paul Maguire
PURPOSE: Minzasolmin (UCB0599) is an orally administered, small molecule inhibitor of ASYN misfolding in development as a potential disease-modifying therapy for Parkinson's disease. Here we describe the preclinical development of a radiolabeled tracer and results from a phase 1 study using the tracer to investigate the brain distribution of minzasolmin. PROCEDURES: In the preclinical study, two radiolabeling positions were investigated on the S-enantiomer of minzasolmin (UCB2713): [11 C]methylamine UCB2713 ([11 C-N-CH3 ]UCB2713) and [11 C]carbonyl UCB2713 ([11 C-CO]UCB2713)...
December 18, 2023: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging